Semaglutide

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose regulation, insulin secretion, and appetite signaling. It was developed as a longer-acting GLP-1 receptor agonist and has been studied extensively in both metabolic and cardiovascular research contexts.

Research interest in Semaglutide has expanded significantly in recent years, particularly in models involving type 2 diabetes, obesity, non-alcoholic fatty liver disease, and cardiovascular risk. The compound's extended half-life (~one week) compared to native GLP-1 makes it well-suited for longer research protocols.

Research Applications

• Metabolic disease models — Glucose homeostasis, insulin secretion, and T2DM research
• Obesity research — Appetite regulation, body weight outcomes, adipose tissue studies
• Cardiovascular research — Cardiovascular risk factor modulation in preclinical models
• NAFLD/liver research — Non-alcoholic fatty liver disease and hepatic lipid metabolism

Specifications

• Molecular Weight: ~4,113.6 g/mol
• Form: White lyophilized powder
• Purity: ≥99% (HPLC verified)
• Storage: −20°C, protected from light; reconstitute with bacteriostatic water

Note: Semaglutide is subject to regulatory controls in some jurisdictions. Researchers are responsible for compliance with all applicable local laws and regulations.